OUR MISSION
Is to develop high value, differentiated cardiovascular therapeutics based on validated targets and modes of action
R&D programs Targeted diseasesNews
15.11.2010
Biocitech Park, Paris (France), November...
15.11.2010
Parc Biocitech, Paris (France), le 15 no...
13.07.2010
Biocitech Park, Paris (France), July ...
13.07.2010
Parc Biocitech, Paris (France), le 8 ...
Latest News
Endotis Pharma initiates phase IIa study of first-in-class neutralizable anticoagulant in open-heart surgeryBiocitech Park, Paris, France, June 22, 2011
Endotis Pharma, a world leader in the development of neutralizable anticoagulants, today announced enrolment of the first patients into a Phase IIa study using EP217609 and...
Latest Publications
Specificity and selectivity profile of EP217609: a new neutralizable dual-actionanticoagulant that targets thrombin and factor Xa, Blood Plenary paper 2012 119: 2187 2195Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and factor Xa
Steven T. Olson, Richard Swa...